MYX 0.66% $4.60 mayne pharma group limited

Ann: Non-Executive Director retirement, page-38

  1. 140 Posts.
    lightbulb Created with Sketch. 33
    there's no surge in sales in 2H23..~7m..only thing that surged is costs..it is quite clear from the performance of these 2 highly paid folks (ceo and cfo), they don't have experience in business turnaround..not expect much different to what scott was did during his tenure..

    sean made a comment that nextstellis will be ebitda positive 1H24...with current revenue run rate of 14m and cost of 50m, it will take miracle to achieve this. the guy will come out with more excuses..
    Last edited by mikyc: 01/09/23
 
watchlist Created with Sketch. Add MYX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.